Management of advanced genitourinary tumors.
The management of advanced genitourinary tumors is rapidly evolving thanks to the clinical availability of several targeted drugs with different mechanisms of action. Among clinicians, in-depth knowledge of all the aspects of the disease, together with the capacity to interpret and accurately correlate clinical data and imaging findings, are strongly needed. Moreover, the optimization of treatment sequences might lead to better disease control with respect to prognostic categories, radiological monitoring and newer biomarkers. Among the genitourinary tumors, only few data are available on bladder, testicular and penile cancers. Our report is supported by scientific and clinical experience in renal cell carcinoma and prostate cancer.
Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Filippo
F
Pietrantonio
Pamela
P
Biondani
Elena
E
Verzoni
Giuseppe
G
Procopio
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D019317:Evidence-Based Medicine; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods; D009919:Orchiectomy; D049268:Positron-Emission Tomography / Q000379:methods; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014565:Urogenital Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D019788:Fluorodeoxyglucose F18; D011505:Protein-Tyrosine Kinases; D017430:Prostate-Specific Antigen